镰状细胞病患者造血干细胞移植前后红细胞存活的体内测量
本研究采用生物素标记红细胞,比较镰状细胞病(SCD)移植前6例、移植后5例、镰状细胞特质(HbAS)6例及健康供者(HbAA)3例的红细胞寿命;SCD移植前平均红细胞寿命64.1天,显著短于移植后113.4天、HbAS 126.0天和HbAA 123.7天(P<.001),且红细胞寿命与脱氧后平均最终镰变红细胞比例强相关(P<.001)。
要点
- SCD移植前红细胞平均寿命64.1天,显著短于移植后113.4天(P<.001)。
- 红细胞寿命与脱氧后平均最终镰变红细胞比例强相关(P<.001)。
- 生物素标记红细胞是评估SCD移植前后红细胞存活的安全可行方法。
核心结论
- 生物素标记红细胞是评估SCD患者移植前后红细胞存活的安全可行方法。
- 理解红细胞存活差异可能最终指导基因治疗方案确定逆转SCD表型所需的血红蛋白组成。
研究设计与样本
- 采用生物素标记红细胞测定红细胞寿命,比较SCD移植前、SCD移植后、HbAS和HbAA参与者的红细胞寿命。
- 共纳入20例参与者进行分析:SCD移植前6例、SCD移植后5例、HbAS 6例、HbAA 3例。
- 试验注册号为NCT04476277。
主要发现
- SCD移植前平均红细胞寿命64.1天(范围35-91),显著短于SCD移植后113.4天(范围105-119)、HbAS 126.0天(范围119-147)和HbAA 123.7天(范围91-147)(P<.001)。
- 红细胞寿命与多种血液学参数相关,并与脱氧后平均最终镰变红细胞比例强相关(P<.001)。
- 未发生可归因于生物素使用及相关操作的不良事件。
临床怎么用
- 作者认为,理解红细胞存活差异可能最终指导基因治疗方案确定逆转SCD表型所需的血红蛋白组成,因其与红细胞存活直接相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stable, mixed-donor-recipient chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with sickle cell disease (SCD) is sufficient for phenotypic disease reversal, and results from differences in donor/recipient-red blood cell (RBC) survival. Understanding variability and predictors of RBC survival among patients with SCD before and after HSCT is critical for gene therapy research which seeks to generate sufficient corrected hemoglobin to reduce polymerization thereby overcoming the red cell pathology of SCD. This study used biotin labeling of RBCs to determine the lifespan of RBCs in patients with SCD compared with patients who have successfully undergone curative HSCT, participants with sickle cell trait (HbAS), and healthy (HbAA) donors. Twenty participants were included in the analysis (SCD pre-HSCT: N = 6, SCD post-HSCT: N = 5, HbAS: N = 6, and HbAA: N = 3). The average RBC lifespan was significantly shorter for participants with SCD pre-HSCT (64.1 days; range, 35-91) compared with those with SCD post-HSCT (113.4 days; range, 105-119), HbAS (126.0 days; range, 119-147), and HbAA (123.7 days; range, 91-147) (P<.001). RBC lifespan correlated with various hematologic parameters and strongly correlated with the average final fraction of sickled RBCs after deoxygenation (P<.001). No adverse events were attributable to the use of biotin and related procedures. Biotin labeling of RBCs is a safe and feasible methodology to evaluate RBC survival in patients with SCD before and after HSCT. Understanding differences in RBC survival may ultimately guide gene therapy protocols to determine hemoglobin composition required to reverse the SCD phenotype as it relates directly to RBC survival. This trial was registered at www.clinicaltrials.gov as #NCT04476277.
引用
- Leonard AK, Furstenau D, Inam Z, et al. In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation. Blood Adv. 2024. PMID: 38181784. doi:10.1182/bloodadvances.2023011397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。